Mostrar el registro sencillo del ítem

Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community

dc.rights.licenseopenen_US
dc.contributor.authorMEGRAUD, Francis
dc.contributor.authorBRUYNDONCKX, Robin
dc.contributor.authorCOENEN, Samuel
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorWITTKOP, Linda
dc.contributor.authorHUANG, Te-Din
dc.contributor.authorHOEBEKE, Martin
dc.contributor.authorBENEJAT, Lucie
dc.contributor.authorLEHOURS, Philippe
dc.contributor.authorGOOSSENS, Herman
dc.contributor.authorGLUPCZYNSKI, Youri
dc.contributor.authorEUROPEAN HELICOBACTER PYLORI ANTIMICROBIAL SUSCEPTIBILITY TESTING WORKING, Group
dc.date.accessioned2021-06-30T08:29:37Z
dc.date.available2021-06-30T08:29:37Z
dc.date.issued2021-04-09
dc.identifier.issn0017-5749en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/94927
dc.description.abstractEnOBJECTIVE: Our aim was to prospectively assess the antibiotic resistance rates in Helicobacter pylori strains in Europe in 2018 and to study the link between antibiotic consumption in the community and H. pylori resistance levels in the different countries. DESIGN: The proportion of primary antibiotic resistance cases of H. pylori and their corresponding risk factors were investigated in 24 centres from 18 European countries according to a standardised protocol. Data on antibiotic consumption in the community were collected for the period 2008-2017. The link between antibiotic consumption and resistance data was assessed using generalised linear mixed models. The model with the best fit was selected by means of the Akaike Information Criterion. RESULTS: H. pylori resistance rates for the 1211 adult patients included were 21.4% for clarithromycin, 15.8% for levofloxacin and 38.9% for metronidazole and were significantly higher in Central/Western and Southern than in the Northern European countries.The best model fit was obtained for the Poisson distribution using 2013 consumption data. A significant association was found between H. pylori clarithromycin resistance and consumption in the community of macrolides (p=0.0003) and intermediate-acting macrolides (p=0.005), and between levofloxacin resistance and consumption of quinolones (p=0.0002) and second-generation quinolones (p=0.0003). CONCLUSION: This study confirms the positive correlation between macrolide and quinolone consumption in the community and corresponding H. pylori resistance in European countries. Hence, H. pylori treatment with clarithromycin and levofloxacin should not be started without susceptibility testing in most European countries.
dc.language.isoENen_US
dc.subject.enHelicobacter pylori infection
dc.subject.enAntibiotics
dc.subject.enDrug resistance
dc.subject.enGastric diseases
dc.title.enHelicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community
dc.typeArticle de revueen_US
dc.identifier.doi10.1136/gutjnl-2021-324032en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed33837118en_US
bordeaux.journalGuten_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamMORPH3Eusen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03274476
hal.version1
hal.date.transferred2021-06-30T08:29:42Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Gut&rft.date=2021-04-09&rft.eissn=0017-5749&rft.issn=0017-5749&rft.au=MEGRAUD,%20Francis&BRUYNDONCKX,%20Robin&COENEN,%20Samuel&WITTKOP,%20Linda&HUANG,%20Te-Din&rft.genre=article


Archivos en el ítem

ArchivosTamañoFormatoVer

No hay archivos asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem